Drugs: Licensing

Department of Health and Social Care written question – answered at on 2 February 2023.

Alert me about debates like this

Photo of Chris Green Chris Green Conservative, Bolton West

To ask the Secretary of State for Health and Social Care, how many and what proportion of health technology appraisals conducted by NICE for follow-on indications have resulted in (a) termination, (b) a negative recommendation, (c) an optimised recommendation, (d) a positive recommendation and (e) a recommendation for use within the (i) Cancer Drugs Fund and (ii) and Innovative Medicines Fund.

Photo of Will Quince Will Quince Minister of State (Department of Health and Social Care)

Between 1 January 2017 and 31 December 2022 31% of appraisals of licence extensions by the National Institute for Health and Care Excellence (NICE) were terminated due to the company not making an evidence submission to NICE. Of the licence extensions appraised by NICE 10% were not recommended, 37% were recommended for routine commissioning, 34% were optimised recommendations and 20% were recommended or optimised for use within the Cancer Drugs Fund. No applications were recommended for the Innovative Medicines fund.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.